v3.26.1
Property and Equipment, net
 3 Months Ended 12 Months Ended
Mar. 31, 2026
Sep. 30, 2025
Property, Plant, and Equipment [Abstract]    
Property and Equipment, net

Note 4 — Property and Equipment, net

 

Property and equipment, net consists of the following:

 

    Estimated Useful   March 31,     September 30,  
    Life (years)   2026     2025  
                 
Equipment and furniture   5 - 7   $ 400     $ 400  
Laboratory equipment   5     690       681  
Leasehold improvements   Shorter of estimated useful life or remaining lease term     41       41  
Property and equipment, gross         1,131       1,122  
Less: Accumulated depreciation         (881 )     (794 )
Property and equipment, net       $ 250     $ 328  

 

Depreciation expense for the three months ended March 31, 2026 and 2025 was $29 and $123, respectively. Depreciation expense for the six months ended March 31, 2026 and 2025 was $78 and $246, respectively.

 

Note 6 — Property and Equipment, net

 

Property and equipment, net consists of the following:

  

          
   Estimated Useful Life  September 30, 
   (years)  2025   2024 
            
Equipment and furniture  5 - 7  $400   $948 
Laboratory equipment  5   681    687 
Leasehold improvements  Shorter of estimated useful life or remaining lease term   41    891 
Property and equipment, gross      1,122    2,526 
Less: Accumulated depreciation      (794)   (1,349)
Property and equipment, net     $328   $1,177 

 

Depreciation expense for the years ended September 30, 2025 and 2024 was $366 and $472, respectively.

 

During the year ended September 30, 2025, the Company recognized losses of $472 on the disposal of certain assets, principally consisting of equipment and furniture and leasehold improvements, at a leased office the Company vacated. Such losses are principally included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss. During the year ended September 30, 2024, the Company wrote off certain tooling having a carrying value of $584 which management determined it would not use in production. The charge is included in “Research and development” in the consolidated statements of operations and comprehensive loss.

 

 

MOBIX LABS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

(in thousands, except share and per share amounts)